WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has acquired rights to three products from Teva Pharmaceuticals in connection with Teva’s acquisition of Cephalon.

Par said Tuesday that under the agreement with Teva, Par will own the abbreviated new drug applications (ANDAs) of fentanyl citrate lozenges, a generic version of Actiq, and cyclobenzaprine ER capsules, the generic version of Amrix, as well as the U.S. rights to market modafinil tablets, the generic version of Provigil.

Fentanyl citrate is a narcotic pain medicine for treating breakthrough pain in cancer patients, while cyclobenzaprine is used as a muscle relaxer for the treatment of pain or injury. Modafinil is used to improve wakefulness in adults with sleep disorders such as narcolepsy, obstructive sleep apnea and shift work disorder.

Citing figures from IMS Health, Par reported that annual U.S. sales Actiq and the equivalent generic products are $173 million. Annual U.S. sales for Provigil and Amrix are about $1.1 billion and $125 million, respectively.

Par added that it’s currently shipping all strengths of fentanyl citrate lozenges that were previously available from Teva, while cyclobenzaprine ER capsules and modafinil tablets weren’t previously marketed by Teva and aren’t yet available.

Teva completed its $6.8 billion acquisition of Cephalon last week.